Metronomic Capecitabine Gives Durable 10‑Year DFS Benefit in Early Triple‑Negative Breast Cancer — FOXC1 May Identify Who Benefits
A 10‑year follow‑up of SYSUCC‑001 shows 1 year of metronomic capecitabine after standard adjuvant therapy improved disease‑free survival in early triple‑negative breast cancer; FOXC1 expression emerged as a potential predictive biomarker in exploratory analyses.